Arcturus Therapeutics Holdings Inc.
WHO'M
ai
Digital Profiler. Simply click the AI button
FIGI: BBG00NNW8JK1
ARCT
Arcturus Therapeutics Holdings Inc.
GICS: -
·
Sector: Healthcare
·
Sub-Sector: Biotechnology
NAME
Arcturus Therapeutics Holdings Inc.
ISIN
US03969T1097
TICKER
ARCT
MIC
XNAS
REUTERS
ARCT.OQ
BLOOMBERG
ARCT US
Financial Intelligence
FOR INVESTORS
FOR TRADERS
Securities Trading
Warrants
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Tue, 19.11.2024
Arcturus Therapeutics
US03969T1097
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will present at Jefferies London Healthcare Conference in London, on Wed...
Arcturus Therapeutics
Thu, 14.11.2024
Arcturus Therapeutics
US03969T1097
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi; hereinafter referred to as "Meiji Seika Pharma") today announced its investment in ARCALIS, Inc. (Headquarters: Minami-soma City, Fukushima Prefecture; President: Satoshi Takamatsu; hereinafter referred to as "ARCALIS").
ARCALIS...
Arcturus Therapeutics
Mon, 11.11.2024
Arcturus Therapeutics
US03969T1097
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a “Study Can Proceed” notific...
Arcturus Therapeutics
Thu, 07.11.2024
Arcturus Therapeutics
US03969T1097
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the third quarter ended September 30, 2024, and provided corpor...
Arcturus Therapeutics
Thu, 31.10.2024
Arcturus Therapeutics
US03969T1097
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA vaccines and medicines company focused on the development of infectious disease vaccines and addressing unmet medical needs within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ...
Arcturus Therapeutics
Mon, 30.09.2024
Arcturus Therapeutics
US03969T1097
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and self-amplifying messenger RNA (sa-mRNA) pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced the results of a head-to-head study demonstrating that self-amplifying (sa-mRNA) COVID-19 vaccine maintained superior immunogenicity compared to the conventional mRNA vaccine Comirnaty® for...
Arcturus Therapeutics
Fri, 13.09.2024
Arcturus Therapeutics
US03969T1097
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and sa-mRNA pioneer Arcturus Therapeutics today announced that Japan's Ministry of Health, Labor and Welfare (MHLWs) granted approval and authorization for their updated self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, KOSTAIVE®. The updated vaccine is targeted to protect against the JN.1 line...
Arcturus Therapeutics
Tue, 03.09.2024
Arcturus Therapeutics
US03969T1097
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and addressing unmet medical needs within liver and respiratory rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a “Study May Pro...
Arcturus Therapeutics
Tue, 27.08.2024
Arcturus Therapeutics
US03969T1097
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and addressing unmet medical needs within liver and respiratory rare diseases, today announced that the Company will participate in the following investor and scientific c...
Arcturus Therapeutics
Information on product placements
